Cerulean doses first patient in Phase 2 study of small cell lung cancer drug
US based clinical-stage company Cerulean Pharma has dosed the first patient in a randomised Phase 2 study of its anti-cancer drug for treating extensive-stage small cell lung cancer (SCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Pharmaceuticals | Small Cell Lung Cancer | Study